These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer. Diamond E; Garcias Mdel C; Karir B; Tagawa ST Curr Treat Options Oncol; 2015 Feb; 16(2):9. PubMed ID: 25762124 [TBL] [Abstract][Full Text] [Related]
25. miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics. Sossey-Alaoui K; Plow EF Mol Cancer Res; 2016 Feb; 14(2):228-38. PubMed ID: 26474967 [TBL] [Abstract][Full Text] [Related]
31. Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience. Francini E; Fiaschi AI; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G Anticancer Drugs; 2015 Sep; 26(8):884-7. PubMed ID: 26053281 [TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; Maines F; Veccia A; Galligioni E Urol Oncol; 2015 Jun; 33(6):265.e15-21. PubMed ID: 25907622 [TBL] [Abstract][Full Text] [Related]
33. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736 [TBL] [Abstract][Full Text] [Related]
34. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer]. Ecstein-Fraisse E; Su Z Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866 [TBL] [Abstract][Full Text] [Related]
35. Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. Kroon J; Kooijman S; Cho NJ; Storm G; van der Pluijm G Trends Pharmacol Sci; 2016 Jun; 37(6):451-462. PubMed ID: 27068431 [TBL] [Abstract][Full Text] [Related]
36. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. Bracarda S; Logothetis C; Sternberg CN; Oudard S BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150 [TBL] [Abstract][Full Text] [Related]
38. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897 [TBL] [Abstract][Full Text] [Related]
39. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO; Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992 [TBL] [Abstract][Full Text] [Related]
40. Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in change. Dediu M; Bratu F; Amarandei M; Fejer E J BUON; 2016; 21(6):1379-1382. PubMed ID: 28039695 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]